Latest Ratios: P/E Ratio -7.0x · EV/EBITDA N/A · ROE -104.5%. (2019–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $116M | $606M | $1.1B | $617M | — | — | — |
| Enterprise Value | $141M | $772M | $1.2B | $553M | — | — | — |
| P/E Ratio → | -6.99 | — | — | 1.97 | — | — | — |
| P/S Ratio | 19.47 | 14.92 | 13.61 | 0.63 | — | — | — |
| P/B Ratio | 3.39 | 2.60 | — | 3.75 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 19.02 | 14.92 | 0.56 | — | — | — |
| EV / EBITDA | — | — | — | 22.47 | — | — | — |
| EV / EBIT | — | — | — | 2.70 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 28.6% | 28.6% | -132.1% | 23.4% | -10.4% | 40.3% | — |
| Operating Margin | -242.7% | -242.7% | -332.9% | 2.1% | -453.3% | -1735.9% | — |
| Net Profit Margin | -278.8% | -278.8% | -322.7% | 3.2% | -443.6% | -1772.9% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -104.5% | -104.5% | -341.3% | 44.5% | — | — | — |
| ROA | -23.4% | -23.4% | -70.5% | 4.9% | -36.0% | -90.5% | -50.4% |
| ROIC | -30.4% | -30.4% | -209.5% | — | — | — | — |
| ROCE | -38.3% | -38.3% | -179.0% | 25.7% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.85 | 0.85 | — | 0.14 | — | — | — |
| Debt / EBITDA | — | — | — | 0.96 | — | — | — |
| Net Debt / Equity | — | 0.71 | — | -0.39 | — | — | — |
| Net Debt / EBITDA | — | — | — | -2.61 | — | — | — |
| Debt / FCF | — | — | — | — | -3.59 | — | -0.44 |
| Interest Coverage | -14.25 | -14.25 | -283.45 | — | -350.72 | -9852.14 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.75 | 1.75 | 0.52 | 1.57 | 0.96 | 0.54 | 0.63 |
| Quick Ratio | 1.61 | 1.61 | 0.46 | 1.02 | 0.73 | 0.47 | 0.63 |
| Cash Ratio | 1.31 | 1.31 | 0.21 | 0.50 | 0.29 | 0.33 | 0.33 |
| Asset Turnover | — | 0.07 | 0.22 | 2.68 | 0.04 | 0.03 | — |
| Inventory Turnover | 0.97 | 0.97 | 14.12 | 7.37 | 0.20 | 0.18 | — |
| Days Sales Outstanding | — | 462.17 | 8.10 | 8.81 | 306.11 | 200.07 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 50.8% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $68M | $59M | $54M | $52M | $52M | $40M |
Existential liquidity and insolvency
Based on reported figures, Nano Labs trades at a price-to-sales ratio of 19.47, a valuation that appears disconnected from the company's -48.18% revenue decline and suggests investors are pricing the equity as a speculative option on a potential, yet unproven, turnaround in crypto-mining hardware demand.
The extreme P/S multiple relative to the company's contracting revenue base suggests that the market may be assigning value to the firm's intellectual property or potential pivot to AI-related hardware rather than its current transactional business. Investors should monitor whether this premium can be sustained as the company continues to report significant net losses and fails to demonstrate a clear path to profitability.
As reported in financial statements, Nano Labs' ROIC has remained deeply negative, reaching -2.0% in 2025Q2, which indicates that the company is consistently destroying shareholder value rather than compounding it through its specialized semiconductor design and manufacturing activities.
The inability to generate positive returns on invested capital appears structural, driven by a combination of high R&D overhead and a failure to achieve the scale necessary to amortize fixed costs. This trend suggests that the firm's current capital allocation strategy is failing to produce a competitive advantage, warranting further investigation into the viability of its long-tail crypto-asset focus.
According to recent quarterly data, the company's cash conversion cycle has ballooned to 531 days, a figure that highlights severe inefficiencies in inventory management and suggests that Nano Labs is struggling to move its specialized hardware in a market characterized by rapidly shifting network protocols.
The exceptionally high days inventory outstanding, which reached 1378 days in 2025Q2, implies that the company is holding significant amounts of potentially obsolete hardware. This inventory overhang poses a material risk to future margins, as the firm may be forced to take aggressive write-downs to clear stock in an increasingly competitive semiconductor landscape.
Based on the latest quarterly filings, Nano Labs' debt-to-equity ratio has risen to 1.11, a level that appears increasingly unsustainable given the company's negative interest coverage ratio of -6.85 and its ongoing inability to generate positive operating cash flow to service these mounting financial obligations.
The reliance on debt financing to sustain operations in the face of persistent losses suggests that the company's balance sheet is becoming increasingly vulnerable to credit market volatility. Investors should monitor the firm's ability to refinance these obligations, as the current trajectory may necessitate further dilutive equity raises to avoid a liquidity crisis.
The price-to-book ratio of 3.39 is frequently misapplied to Nano Labs, as it obscures the reality that the company's book value is heavily influenced by recent dilutive financing rather than the accumulation of productive, income-generating assets within its fabless semiconductor business model.
Relying on P/B in this context is misleading because it ignores the rapid erosion of equity through accumulated deficits and the high probability of future inventory write-downs. A more appropriate focus would be on the company's cash burn rate and its ability to maintain liquidity, as these metrics provide a clearer picture of the firm's survival prospects than accounting-based book value.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NA stock.
Nano Labs Ltd's current P/E ratio is -7.0x. The historical average is 2.0x.
Nano Labs Ltd's return on equity (ROE) is -104.5%. The historical average is -133.8%.
Based on historical data, Nano Labs Ltd is trading at a P/E of -7.0x. Compare with industry peers and growth rates for a complete picture.
Nano Labs Ltd has 28.6% gross margin and -242.7% operating margin.